Recent News

• 03.20.2025 - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
• 03.12.2025 - Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
• 03.11.2025 - Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit
• 12.19.2024 - Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
• 12.10.2024 - Facilities and Production Maintenance Manager

Recent Filings

• 03.12.2025 - EX-99.1 EX-99.1
• 03.12.2025 - 8-K Current report
• 03.12.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.07.2025 - 4 Statement of changes in beneficial ownership of securities